Egészségbiztonság Nemzeti Laboratórium(RRF-2.3.1-21-2022-00006) Támogató: NKFIH
Influenza A viruses circulated in Europe from September 2023 to January 2024, with
influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine
effectiveness (IVE) estimates from two European studies, covering 10 countries across
primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against
A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to
63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44%
(95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.